Ignite Creation Date:
2024-05-06 @ 3:04 PM
Last Modification Date:
2024-10-26 @ 1:42 PM
Study NCT ID:
NCT04515394
Status:
TERMINATED
Last Update Posted:
2022-12-22
First Post:
2020-08-11
Brief Title:
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RASBRAF Wild Type Metastatic Colorectal Cancer PERSPECTIVE
Sponsor:
EMD Serono Research Development Institute Inc
Organization:
EMD Serono
Study Overview
Official Title:
A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RASBRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification PERSPECTIVE
Status:
TERMINATED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
The study was terminated early due to operational challenges identifying suitable participants for screening in the study
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study was to assess the preliminary antitumor activity safety and tolerability of tepotinib in combination with cetuximab in participants with RASBRAF wild-type left-sided Metastatic Colorectal Cancer mCRC having acquired resistance to anti-epidermal growth factor receptor EGFR antibody targeted therapy due to mesenchymal epithelial transition MET amplification
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-001776-15 | EUDRACT_NUMBER | None | None |